Stockscreener 앱 받기
1.62
6.36%
-0.11
시간 외 거래:
1.63
0.010
+0.62%
전일 마감가:
$1.73
열려 있는:
$1.7
하루 거래량:
115.87K
Relative Volume:
0.04
시가총액:
$4.51M
수익:
-
순이익/손실:
$-18.35M
주가수익비율:
-1.3966
EPS:
-1.16
순현금흐름:
$-19.20M
1주 성능:
-7.43%
1개월 성능:
+27.56%
6개월 성능:
-98.91%
1년 성능:
-99.42%
1일 변동 폭
$1.62
$1.72
1주일 범위
$1.5801
$1.7896
52주 변동 폭
$1.14
$427.81
Theriva Biologics Inc Stock (TOVX) Company Profile
명칭
Theriva Biologics Inc
전화
301 417 4364
주소
9605 Medical Center Drive, Suite 270, Rockville
TOVX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
1.62 | 4.51M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.32 | 105.15B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
730.30 | 80.25B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
648.62 | 38.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.95 | 30.43B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
126.88 | 30.42B | 3.30B | -501.07M | 1.03B | -2.1146 |
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst - Benzinga
Synthetic Biologics stock hits 52-week low at $1.21 - Investing.com India
Synthetic Biologics stock hits 52-week low at $1.21 By Investing.com - Investing.com UK
Theriva Biologics outlines Phase 3 study for cancer drug By Investing.com - Investing.com Canada
Theriva™ Biologics Announces U.S. FDA Guidance on Design of - GlobeNewswire
Theriva Biologics Gets FDA Guidance on VCN-01 Phase 3 Trial Design for Pancreatic Cancer Treatment - StockTitan
Synthetic Biologics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
Synthetic Biologics stock hits 52-week low at $1.24 - Investing.com
Maxim Group Has Lowered Expectations for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price - Defense World
Theriva Biologics Highlights Key Achievements in Q3 2024 - TipRanks
Theriva Biologics: Q3 Earnings Snapshot - Houston Chronicle
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
What's Going On With Theriva Biologics Stock Friday? - MSN
Theriva Biologics Expands Stock Plans and Share Authority - TipRanks
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant - The Manila Times
Theriva Biologics gains EU orphan drug status for eye cancer treatment - Investing.com
Theriva Biologics Announces Orphan Medicinal Product - GlobeNewswire
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - StockTitan
Check out these key findings about Theriva Biologics Inc (TOVX) - SETE News
Theriva Biologics Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Was Theriva Biologics Inc (TOVX)’s session last reading good? - US Post News
Market cap of Theriva Biologics Inc [TOVX] reaches 4.06M – now what? - The DBT News
Closing Figures: Theriva Biologics Inc (TOVX)’s Positive Finish at 1.79, Up 44.35 - The Dwinnex
Theriva reports progress in phase 1b/2a trial of SYN-004 By Investing.com - Investing.com South Africa
Synthetic Biologics stock plunges to 52-week low of $1.24 By Investing.com - Investing.com Australia
Theriva reports progress in phase 1b/2a trial of SYN-004 - Investing.com Australia
OMER Stock Falls 5.35% Amid Mixed Institutional Ratings - GuruFocus.com
Halozyme (HALO) Stock Surges Amid Positive Earnings and Analyst Ratings - GuruFocus.com
Crude Oil Jumps Over 4%; US Services PMI Revised Lower - Benzinga
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients - Benzinga
Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients - Seeking Alpha
Theriva Biologics Advances SYN-004 in Clinical Trial - TipRanks
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Manila Times
Theriva™ Biologics Announces Positive Outcome of Data and - GlobeNewswire
Synthetic Biologics stock plunges to 52-week low of $1.24 - Investing.com India
Was anything negative for Theriva Biologics Inc (TOVX) stock last session? - US Post News
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - MSN
Theriva Biologics dips 11%, prices 2.5M equity offering - MSN
Theriva Biologics Announces Pricing of $2.5 Million Public Offering - StockTitan
Theriva Biologics Inc (TOVX) Stock: From Low to High in 52 Weeks - The InvestChronicle
Understanding TOVX stock ratios for better investment decisions - US Post News
Theriva Biologics Inc (TOVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.46%
3.07%
자본화:
|
볼륨(24시간):